Key Takeaways
Extended Takeaways
- Mood disorders accounted for 11 (50.0%) of approvals, while only 2 (9.1%) targeted attention-deficit/hyperactivity disorder and 3 (13.6%) targeted other disorders, suggesting continued concentration of development in a few high-volume indications rather than broader coverage of unmet psychiatric needs.
- Three (13.6%) approvals were combinations or reformulations of existing drugs, so clinicians should not assume a newly approved psychiatric product represents a mechanistic advance over established options.
- External assessment was sparse even among drugs approved before 2023: Prescrire rated 3 drugs (13.6%) as “clinically not useful,” and the remaining 16 drugs (72.7%) received no rating, limiting independent confirmation of real-world value for many newer agents.
- Expedited regulatory pathways were used infrequently, with 4 drugs (18.2%) receiving expedited FDA approval and 3 (13.6%) designated as “breakthrough” drugs, indicating that most approvals did not meet criteria for unusually strong early signals of clinical advance.
- Only 1 drug (4.5%), aripiprazole, held orphan drug status for Tourette disorder and was included on the WHO’s Model List of Essential Medicines, underscoring how rarely recent psychiatric approvals have also achieved markers of public health importance beyond FDA clearance.
